Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study'

被引：0
|
作者：
Zhu, Xudong [1 ,2 ]
机构：
[1] China Med Univ, Dalian Univ Technol, Liaoning Canc Hosp & Inst, Dept Gen Surg,Canc Hosp, Shenyang, Liaoning, Peoples R China
[2] Liaoning Prov Key Lab Precis Med Malignant Tumors, Shenyang, Liaoning, Peoples R China
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2025年 / 13卷 / 03期
关键词：
Immunotherapy; Lung Cancer;
D O I：
10.1136/jitc-2025-011845
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Real-world treatment sequencing in advanced non-small cell lung cancer (aNSCLC).
    Radtchenko, Janna
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Wang, Fen
    Jin, Feng
    Cheng, Boran
    Zhang, Yue
    Zhou, Qing
    Wang, Shubin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (07) : 1721 - 1735
  • [23] Contemporary management of advanced non-small cell lung cancer aNSCLC) in a large, real-world cohort.
    Presley, Carolyn Jean
    Harrington, Eoghan
    Gippetti, James
    Agarwala, Vineeta
    Bowser, Bryan
    Adelson, Kerin B.
    Herbst, Roy S.
    Abernethy, Amy Pickar
    Gross, Cary Philip
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study
    Mu, Yuxin
    Xing, Puyuan
    Hao, Xuezhi
    Wang, Yan
    Li, Junling
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 9243 - 9251
  • [25] A retrospective cohort study of sintilimab and pembrolizumab as first-line treatments for advanced non-small cell lung cancer
    Wu, Kai
    Fu, Yifan
    Zeng, Daxiong
    Chen, Tao
    Wang, Changguo
    Jiang, Junhong
    JOURNAL OF THORACIC DISEASE, 2022, 14 (03) : 679 - 688
  • [26] A real-world study in advanced non-small cell lung cancer with de novo brain metastasis
    Lei, Lei
    Wang, Wen-xian
    Wang, Dong
    Lin, Li
    Zhu, You-cai
    Wang, Hong
    Wang, Li-ping
    Zhuang, Wu
    Fang, Mei-yu
    Wan, Bing
    Feng, Hui-jing
    Xu, Chun-wei
    JOURNAL OF CANCER, 2021, 12 (05): : 1467 - 1473
  • [27] Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study
    Zhong, Qiuxia
    Liu, Zhihua
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4115 - 4128
  • [28] A real-world analysis of non-small cell lung cancer patients treated with pembrolizumab or pembrolizumab in combination with pemetrexed and platinum
    Agg, Himani
    Winfree, Katherine B.
    Zhu, Yajun Emily
    Muehlenbein, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [29] Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
    Fantoni, A.
    Warburton, L.
    Solomon, B.
    Alexander, M.
    Maddula, M.
    Da Silva, I. Pires
    Brown, L. J.
    Nagrial, A.
    Abu Al-Hial, F.
    Itchins, M.
    Pavlakis, N.
    Bowyer, S. E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1682 - S1683
  • [30] Advanced non-small cell lung cancer - treatment with Pembrolizumab
    Silvinato, Antonio
    Floriano, Idevaldo
    Bernardo, Wanderley Marques
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (03): : 256 - 256
12345